Moderna Inc
MRNA24.770USD
-0.190-0.76%
Close 11/14, 16:00（ET）Quotes delayed by 15 min
9.69BMarket Cap
LossP/E TTM
More Details of Moderna Inc Company
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Moderna Inc Info
Ticker SymbolMRNA
Company nameModerna Inc
IPO dateDec 07, 2018
CEOMr. Stephane Bancel
Number of employees5800
Security typeOrdinary Share
Fiscal year-endDec 07
Address325 Binney Street
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02142
Phone16177146500
Websitehttps://www.modernatx.com/
Ticker SymbolMRNA
IPO dateDec 07, 2018
CEOMr. Stephane Bancel
Company Executives of Moderna Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
--
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
--
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
28.17K
+2.16%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
18.26K
+4.28%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
--
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Dr. Noubar B. Afeyan, Ph.D.
Dr. Noubar B. Afeyan, Ph.D.
Non-Executive Independent Chairman of the Board, Co-Founder
Non-Executive Independent Chairman of the Board, Co-Founder
--
--
Dr. Rose Loughlin
Dr. Rose Loughlin
Executive Vice President - Research
Executive Vice President - Research
--
--
Mr. Jerh Collins
Mr. Jerh Collins
Chief Technical Operations and Quality Officer
Chief Technical Operations and Quality Officer
--
--
Mr. Stephane Bancel
Mr. Stephane Bancel
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
--
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
--
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
28.17K
+2.16%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
18.26K
+4.28%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
--
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
COVID
114.00M
0.00%
RSV
0.00
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
88.00M
77.19%
Rest of the World
26.00M
22.81%
Europe
0.00
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
COVID
114.00M
0.00%
RSV
0.00
0.00%
Shareholding Stats
Updated: 23 hours ago
Updated: 23 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.52%
Baillie Gifford & Co.
5.59%
BlackRock Institutional Trust Company, N.A.
5.12%
State Street Investment Management (US)
4.38%
Two Sigma Investments, LP
3.66%
Other
70.73%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.52%
Baillie Gifford & Co.
5.59%
BlackRock Institutional Trust Company, N.A.
5.12%
State Street Investment Management (US)
4.38%
Two Sigma Investments, LP
3.66%
Other
70.73%
Shareholder Types
Shareholders
Proportion
Investment Advisor
38.96%
Investment Advisor/Hedge Fund
14.16%
Hedge Fund
10.34%
Corporation
4.63%
Research Firm
4.51%
Individual Investor
2.54%
Bank and Trust
1.37%
Venture Capital
1.19%
Pension Fund
1.17%
Other
21.14%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
1925
289.85M
74.21%
-20.82M
2025Q2
2015
310.55M
79.82%
-10.63M
2025Q1
2127
325.75M
84.24%
-21.87M
2024Q4
2176
321.41M
83.21%
-6.67M
2024Q3
2154
311.92M
81.18%
-17.40M
2024Q2
2186
316.03M
82.47%
-13.47M
2024Q1
2203
318.24M
83.12%
-1.14M
2023Q4
2309
311.40M
81.63%
+3.41M
2023Q3
2445
301.25M
79.05%
-6.86M
2023Q2
2461
301.15M
78.90%
-7.01M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
41.62M
10.7%
+1.37M
+3.40%
Jun 30, 2025
Baillie Gifford & Co.
22.09M
5.68%
-2.85M
-11.44%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
19.64M
5.05%
+1.76M
+9.86%
Jun 30, 2025
State Street Investment Management (US)
17.27M
4.44%
-507.93K
-2.86%
Jun 30, 2025
Two Sigma Investments, LP
14.77M
3.8%
+6.51M
+78.82%
Jun 30, 2025
Fidelity Management & Research Company LLC
19.46M
5%
-1.37M
-6.56%
Jun 30, 2025
Geode Capital Management, L.L.C.
8.88M
2.28%
+1.42M
+19.05%
Jun 30, 2025
Boston Biotech Ventures, L.L.C.
9.21M
2.37%
+160.31K
+1.77%
Mar 05, 2025
Theleme Partners LLP
7.87M
2.02%
+626.42K
+8.65%
Jun 30, 2025
D. E. Shaw & Co., L.P.
7.46M
1.92%
+1.83M
+32.42%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
3.76%
Global X Genomics & Biotechnology ETF
3.46%
First Trust NYSE Arca Biotechnology Index Fund
2.38%
SPDR S&P Biotech ETF
2.2%
VanEck Biotech ETF
1.84%
Invesco S&P 500 Equal Weight Health Care ETF
1.75%
Langar Global HealthTech ETF
1.61%
Virtus LifeSci Biotech Products ETF
1.57%
ROBO Global Healthcare Technology & Innovation ETF
1.55%
WisdomTree BioRevolution Fund
1.42%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion3.76%
Global X Genomics & Biotechnology ETF
Proportion3.46%
First Trust NYSE Arca Biotechnology Index Fund
Proportion2.38%
SPDR S&P Biotech ETF
Proportion2.2%
VanEck Biotech ETF
Proportion1.84%
Invesco S&P 500 Equal Weight Health Care ETF
Proportion1.75%
Langar Global HealthTech ETF
Proportion1.61%
Virtus LifeSci Biotech Products ETF
Proportion1.57%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.55%
WisdomTree BioRevolution Fund
Proportion1.42%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
